Heikal O A, Akao T, Takeda S, Hattori M
Research Institute for Wakan-Yaku (Traditional Sino-Japanese Medicines), Toyama Medical and Pharmaceutical University, Sugitani, Japan.
Biol Pharm Bull. 1997 May;20(5):517-21. doi: 10.1248/bpb.20.517.
Plasma concentrations of paeoniflorin (PF) and its major metabolite, paeonimetabolin I (PM-I), were estimated after oral administration of PF to rats at doses of 0.5 and 5 mg/kg. The maximal plasma concentrations (Cmax) of PF were 9.9 and 20.3, and those of PM-I were 16.5 and 101.7 ng/ml at each dose, respectively. The times to Cmax (tmax) of PF were 11.6 and 13.3, and those of PM-I were 60 and 80 min, respectively. The AUC(0-180) of PM-I were 1873 and 12358, and those of PF were 300 and 1174 ng min/ml, respectively. On the other hand, after intravenous administration of PM-I to rats at doses of 0.2 and 2 mg/kg (equal in molar ratio to 0.5 and 5 mg/kg PF), the plasma concentration of PM-I decreased rapidly and the plasma concentration-time curve profile of it fitted well with the two-compartment model at each dose, with terminal half lives (t1/2) of 90.9 and 90.6 min. The Vdss values were 0.91 and 3.79 l/kg, the CLtot values were 8.7 and 39.9 ml/min kg, and the AUC(0-180) values were 5614.1 and 13176.0 ng min/ml, at each dose, respectively. The significant increase in Vdss and CLtot with increasing doses suggested dose-dependent pharmacokinetics. When PM-I was given orally at the same doses, the following parameters were shown: Cmax of 102.2 and 285 ng/ml at tmax 6.2 and 7.5 min and AUCs of 4145.6 and 14182.1 ng min/ml, at each dose. The bioavailability (F) values were 0.8 and 1.07, respectively. These findings indicated that the high percentage of PM-I transformed by intestinal bacteria was rapidly absorbed from the gastrointestinal tract, and a significantly high concentration of PM-I, rather than PF, was present in the plasma after oral administration of PF.
给大鼠分别口服剂量为0.5和5mg/kg的芍药苷(PF)后,测定其血浆中芍药苷及其主要代谢产物芍药代谢物I(PM-I)的浓度。各剂量下PF的最大血浆浓度(Cmax)分别为9.9和20.3ng/ml,PM-I的最大血浆浓度分别为16.5和101.7ng/ml。PF达到Cmax的时间(tmax)分别为11.6和13.3分钟,PM-I达到Cmax的时间分别为60和80分钟。PM-I的AUC(0 - 180)分别为1873和12358ng·min/ml,PF的AUC(0 - 180)分别为300和1174ng·min/ml。另一方面,给大鼠静脉注射剂量为0.2和2mg/kg的PM-I(摩尔比等同于0.5和5mg/kg的PF)后,PM-I的血浆浓度迅速下降,且各剂量下其血浆浓度-时间曲线符合二室模型,末端半衰期(t1/2)分别为90.9和90.6分钟。各剂量下的稳态分布容积(Vdss)值分别为0.91和3.79l/kg,总清除率(CLtot)值分别为8.7和39.9ml/(min·kg),AUC(0 - 180)值分别为5614.1和13176.0ng·min/ml。Vdss和CLtot随剂量增加而显著增加,提示存在剂量依赖性药代动力学。当以相同剂量口服PM-I时,各剂量下显示的参数如下:Cmax分别为102.2和285ng/ml,tmax分别为6.2和7.5分钟,AUC分别为4145.6和14182.1ng·min/ml。生物利用度(F)值分别为0.8和1.07。这些结果表明,肠道细菌转化生成的高比例PM-I能从胃肠道迅速吸收,口服PF后血浆中存在的PM-I浓度显著高于PF。